Abstract
Aptamers are short, single-stranded oligonucleotides that are isolated through a process termed systematic evolution of ligands by exponential enrichment. With the advent of cell-based selection technology, aptamers can be selected to bind protein targets that are expressed on the cell surface. These aptamers demonstrate excellent specificity and high affinity toward their target proteins and are often internalized upon binding to their targets. This has opened up the possibility of using aptamers for cell-specific targeted drug delivery. In this review, we will discuss cell-surface protein targets, the aptamers that bind them, and their applications for targeted therapeutics.
Similar content being viewed by others
References
Adler A, Forster N, Homann M et al (2008) Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High Throughput Screen 11:16–23
Alexis F, Pridgen E, Molnar LK et al (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515
Aravind A, Jeyamohan P, Nair R et al (2012) AS1411 aptamer tagged PLGA–lecithin–PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 109:2920–2931
Bagalkot V, Zhang L, Levy-Nissenbaum E et al (2007) Quantum dot–aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 7:3065–3070
Barciszewski J, Medgaard M, Koch T et al (2009) Locked nucleic acid aptamers. Methods Mol Biol 535:165–186
Bates PJ, Kahlon JB, Thomas SD et al (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274:26369–26377
Bates PJ, Laber DA, Miller DM et al (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86:151–164
Bayrac AT, Sefah K, Parekh P et al (2011) In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci 2:175–181
Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 93:1014–1020
Becker RC, Oney S, Becker KC et al (2007) Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. Hamostaseologie 27:378–382
Berger EA, Doms RW, Fenyo EM et al (1998) A new classification for HIV-1. Nature 391:240
Bombardelli L, Cavallaro U (2010) Immunoglobulin-like cell adhesion molecules: novel signaling players in epithelial ovarian cancer. Int J Biochem Cell Biol 42:590–594
Borkowski S, Dinkelborg LM (2006) Aptamers for in vivo imaging. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 343–362
Bunka DH, Platonova O, Stockley PG (2010) Development of aptamer therapeutics. Curr Opin Pharmacol 10:557–562
Cambier JC, Campbell KS (1992) Membrane immunoglobulin and its accomplices: new lessons from an old receptor. FASEB J 6:3207–3217
Cerchia L, Esposito CL, Camorani S et al (2012) Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 20:2291–2303
Chelliserrykattil J, Ellington AD (2004) Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22:1155–1160
Chen CH, Dellamaggiore KR, Ouellette CP et al (2008) Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105:15908–15913
Cho HS, Dong Z, Pauletti GM et al (2010) Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 4:5398–5404
Chu TC, Marks JW 3rd, Lavery LA et al (2006a) Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 66:5989–5992
Chu TC, Twu KY, Ellington AD et al (2006b) Aptamer mediated siRNA delivery. Nucleic Acids Res 34:e73
Cohen C, Forzan M, Sproat B et al (2008) An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 381:46–54
Dalgleish AG, Beverley PC, Clapham PR et al (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763–767
Daniels DA, Chen H, Hicke BJ et al (2003) A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100:15416–15421
Dassie JP, Liu XY, Thomas GS et al (2009) Systemic administration of optimized aptamer–siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849
Derenzini M, Sirri V, Trere D et al (1995) The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest 73:497–502
Dey AK, Griffiths C, Lea SM et al (2005a) Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 11:873–884
Dey AK, Khati M, Tang M et al (2005b) An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120–CCR5 interaction. J Virol 79:13806–13810
Dhar S, Gu FX, Langer R et al (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356–17361
Dhar S, Kolishetti N, Lippard SJ et al (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108:1850–1855
Ditzler MA, Bose D, Shkriabai N et al (2011) Broad-spectrum aptamer inhibitors of HIV reverse transcriptase closely mimic natural substrates. Nucleic Acids Res 39:8237–8247
Doudna JA, Cech TR, Sullenger BA (1995) Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 92:2355–2359
Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:5623–5637
Eaton BE, Gold L, Zichi DA (1995) Let’s get specific: the relationship between specificity and affinity. Chem Biol 2:633–638
Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822
Esposito CL, Passaro D, Longobardo I et al (2011) A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6:e24071
Eulberg D, Jarosch F, Vonhoff S et al (2006) Spiegelmers for therapeutic applications—use of chiral principles in evolutionary selection techniques. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 417–442
Fabiilli ML, Haworth KJ, Sebastian IE et al (2010) Delivery of chlorambucil using an acoustically triggered perfluoropentane emulsion. Ultrasound Med Biol 36:1364–1375
Farokhzad OC, Cheng J, Teply BA et al (2006a) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315–6320
Farokhzad OC, Karp JM, Langer R (2006b) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 3:311–324
Ferreira CS, Matthews CS, Missailidis S (2006) DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol 27:289–301
Ferreira CS, Cheung MC, Missailidis S et al (2009) Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 37:866–876
Fickert H, Fransson IG, Hahn U (2006) Aptamers to small molecules. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 94–115
Fitzwater T, Polisky B (1996) A SELEX primer. Methods Enzymol 267:275–301
Gao J, Gu H, Xu B (2009) Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res 42:1097–1107
Gao H, Qian J, Cao S et al (2012a) Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33:5115–5123
Gao H, Qian J, Yang Z et al (2012b) Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33:6264–6272
Gendler SJ (2001) MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6:339–353
Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528–539
Ginisty H, Amalric F, Bouvet P (1998) Nucleolin functions in the first step of ribosomal RNA processing. EMBO J 17:1476–1486
Ginisty H, Sicard H, Roger B et al (1999) Structure and functions of nucleolin. J Cell Sci 112(Pt 6):761–772
Gold L, Polisky B, Uhlenbeck O et al (1995) Diversity of oligonucleotide functions. Annu Rev Biochem 64:763–797
Gref R, Minamitake Y, Peracchia MT et al (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603
Guo J, Gao X, Su L et al (2011) Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010–8020
Hicke BJ, Marion C, Chang YF et al (2001) Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276:48644–48654
Hicke BJ, Stephens AW, Gould T et al (2006) Tumor targeting by an aptamer. J Nucl Med 47:668–678
Hovanessian AG, Soundaramourty C, El Khoury D et al (2010) Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS ONE 5:e15787
Hu Y, Duan J, Zhan Q et al (2012) Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7:e31970
Huang Y, Shi H, Zhou H et al (2006) The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107:3564–3571
Huang YF, Shangguan D, Liu H et al (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 10:862–868
Huang J, Xu JS, Xu RX (2010) Heat-sensitive microbubbles for intraoperative assessment of cancer ablation margins. Biomaterials 31:1278–1286
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354
Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957–2962
Jing N, Rando RF, Pommier Y et al (1997) Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry 36:12498–12505
Joseph LF, Ezhevsky S, Scott DW (1995) Lymphoma models for B-cell activation and tolerance: anti-immunoglobulin M treatment induces growth arrest by preventing the formation of an active kinase complex which phosphorylates retinoblastoma gene product in G1. Cell Growth Differ 6:51–57
Kang H, O’Donoghue MB, Liu H et al (2010) A liposome-based nanostructure for aptamer directed delivery. Chem Commun 46:249–251
Kang H, Liu H, Zhang X et al (2011a) Photoresponsive DNA-cross-linked hydrogels for controllable release and cancer therapy. Langmuir 27:399–408
Kang H, Trondoli AC, Zhu G et al (2011b) Near-infrared light-responsive core-shell nanogels for targeted drug delivery. ACS Nano 5:5094–5099
Keefe AD, Cload ST (2008) SELEX with modified nucleotides. Curr Opin Chem Biol 12:448–456
Khati M, Schuman M, Ibrahim J et al (2003) Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 77:12692–12698
Kim D, Jeong YY, Jon S (2010a) A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4:3689–3696
Kim E, Jung Y, Choi H et al (2010b) Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31:4592–4599
Kim JK, Choi KJ, Lee M et al (2012) Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33:207–217
Kotula JW, Pratico ED, Ming X et al (2012) Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther 22:187–195
Kurosaki T, Higuchi N, Kawakami S et al (2012) Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer. Gene 491:205–209
Kutok JL, Aster JC (2002) Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 20:3691–3702
Lai YT, Destefano JJ (2012) DNA aptamers to human immunodeficiency virus reverse transcriptase selected by a primer-free SELEX method: characterization and comparison with other aptamers. Nucleic Acid Ther 22:162–176
Lee IH, An S, Yu MK et al (2011) Targeted chemoimmunotherapy using drug-loaded aptamer–dendrimer bioconjugates. J Control Release 155:435–441
Li N, Larson T, Nguyen HH et al (2010) Directed evolution of gold nanoparticle delivery to cells. Chem Commun 46:392–394
Li J, Feng L, Fan L et al (2011a) Targeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943–4950
Li N, Nguyen HH, Byrom M et al (2011b) Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6:e20299
Liu H, Moy P, Kim S et al (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629–3634
Liu J, Liu H, Kang H et al (2012) Aptamer-incorporated hydrogels for visual detection, controlled drug release, and targeted cancer therapy. Anal Bioanal Chem 402:187–194
Long SB, Long MB, White RR et al (2008) Crystal structure of an RNA aptamer bound to thrombin. RNA 14:2504–2512
Lorenz C, Schroeder R (2006) Aptamers to antibiotics. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 116–130
Lupold SE, Hicke BJ, Lin Y et al (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029–4033
Mackie EJ (1997) Molecules in focus: tenascin-C. Int J Biochem Cell Biol 29:1133–1137
Mallikaratchy P, Tang Z, Kwame S et al (2007) Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt’s lymphoma cells. Mol Cell Proteomics 6:2230–2238
Mallikaratchy P, Tang Z, Tan W (2008) Cell specific aptamer-photosensitizer conjugates as a molecular tool in photodynamic therapy. Chem Med Chem 3:425–428
Mallikaratchy PR, Ruggiero A, Gardner JR et al (2011) A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res 39:2458–2469
McNamara JO 2nd, Andrechek ER, Wang Y et al (2006) Cell type-specific delivery of siRNAs with aptamer–siRNA chimeras. Nat Biotechnol 24:1005–1015
Melikyan GB, Markosyan RM, Hemmati H et al (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151:413–423
Meng L, Yang L, Zhao X et al (2012) Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS ONE 7:e33434
Mi J, Liu Y, Rabbani ZN et al (2010) In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 6:22–24
Midwood KS, Hussenet T, Langlois B et al (2011) Advances in tenascin-C biology. Cell Mol Life Sci 68:3175–3199
Min K, Jo H, Song K et al (2011) Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (−) prostate cancers. Biomaterials 32:2124–2132
Moore MD, Cookson J, Coventry VK et al (2011) Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem 286:2526–2535
Mori T, Oguro A, Ohtsu T et al (2004) RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res 32:6120–6128
Mufhandu HT, Gray ES, Madiga MC et al (2012) UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol 86:4989–4999
Neff CP, Zhou J, Remling L et al (2011) An aptamer–siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3:66ra66
Ng EW, Shima DT, Calias P et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132
Ni X, Castanares M, Mukherjee A et al (2011a) Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18:4206–4214
Ni X, Zhang Y, Ribas J et al (2011b) Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121:2383–2390
Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56:555–583
Nimjee SM, Rusconi CP, Sullenger BA (2006) Aptamers to proteins. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 131–166
Oney S, Lam RT, Bompiani KM et al (2009) Development of universal antidotes to control aptamer activity. Nat Med 15:1224–1228
Ozalp VC, Eyidogan F, Oktem HA (2011) Aptamer-gated nanoparticles for smart drug delivery. Pharmaceuticals 4:1137–1157
Padilla R, Sousa R (1999) Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res 27:1561–1563
Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451
Ramalingam D, Duclair S, Datta SA et al (2011) RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol 85:305–314
Rapoport NY, Kennedy AM, Shea JE et al (2009) Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release 138:268–276
Ray P, Cheek MA, Sharaf ML et al (2012) Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther 22:295–305
Realini T, Ng EWM, Adamis AP (2006) Applications in the clinic: the anti-VEGF aptamer. In: Klussmann S (ed) The aptamer handbook: functional oligonucleotides and their applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 443–460
Rusconi CP, Scardino E, Layzer J et al (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90–94
Rusconi CP, Roberts JD, Pitoc GA et al (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423–1428
Ryou SM, Kim JM, Yeom JH et al (2011) Gold nanoparticle-assisted delivery of small, highly structured RNA into the nuclei of human cells. Biochem Biophys Res Commun 416:178–183
Samson M, Libert F, Doranz BJ et al (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722–725
Shangguan D, Li Y, Tang Z et al (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103:11838–11843
Shangguan D, Cao ZC, Li Y et al (2007) Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem 53:1153–1155
Shangguan D, Cao Z, Meng L et al (2008a) Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7:2133–2139
Shangguan D, Meng L, Cao ZC et al (2008b) Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 80:721–728
Shieh YA, Yang SJ, Wei MF et al (2010) Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 4:1433–1442
Shigdar S, Lin J, Yu Y et al (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991–998
Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235:179–192
Soontornworajit B, Zhou J, Shaw MT et al (2010a) Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. Chem Commun (Camb) 46:1857–1859
Soontornworajit B, Zhou J, Zhang Z et al (2010b) Aptamer-functionalized in situ injectable hydrogel for controlled protein release. Biomacromolecules 11:2724–2730
Sooter LJ, Ellington AD (2002) Reflections on a novel therapeutic candidate. Chem Biol 9:857–858
Soundararajan S, Chen W, Spicer EK et al (2008) The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68:2358–2365
Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J 13:1911–1922
Taghdisi SM, Abnous K, Mosaffa F et al (2010) Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target 18:277–281
Tan L, Neoh KG, Kang ET et al (2011) PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 11:1331–1335
Tan L, Gee Neoh K, Kang ET et al (2012) Designer tridentate mucin 1 aptamer for targeted drug delivery. J Pharm Sci 101:1672–1677
Tang Z, Shangguan D, Wang K et al (2007) Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 79:4900–4907
Tasch J, Gong M, Sadelain M et al (2001) A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 21:249–261
Thiel KW, Giangrande PH (2010) Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 1:849–861
Thiel KW, Hernandez LI, Dassie JP et al (2012) Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40:6319–6337
Thomas MD, Srivastava B, Allman D (2006) Regulation of peripheral B cell maturation. Cell Immunol 239:92–102
Tong GJ, Hsiao SC, Carrico ZM et al (2009) Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 131:11174–11178
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510
Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212
Vavalle JP, Rusconi CP, Zelenkofske S et al (2012) A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. J Thromb Haemost 10:1303–1311
Wan Y, Kim YT, Li N et al (2010) Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer Res 70:9371–9380
Wan Y, Mahmood MA, Li N et al (2012) Nanotextured substrates with immobilized aptamers for cancer cell isolation and cytology. Cancer 118:1145–1154
Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434:365–381
Wang CH, Huang YF, Yeh CK (2011) Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging. Langmuir 27:6971–6976
Wang CH, Kang ST, Lee YH et al (2012) Aptamer-conjugated and drug-loaded acoustic droplets for ultrasound theranosis. Biomaterials 33:1939–1947
Wheeler LA, Trifonova R, Vrbanac V et al (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer–siRNA chimeras. J Clin Invest 121:2401–2412
White RR, Sullenger BA, Rusconi CP (2000) Developing aptamers into therapeutics. J Clin Invest 106:929–934
Wu Y, Sefah K, Liu H et al (2010) DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA 107:5–10
Xiao Z, Shangguan D, Cao Z et al (2008) Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 14:1769–1775
Yang X, Liu X, Liu Z et al (2012) Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater 24:2890–2895
Ye M, Hu J, Peng M et al (2012) Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci 13:3341–3353
Yin J, He X, Wang K et al (2012) One-step engineering of silver nanoclusters-aptamer assemblies as luminescent labels to target tumor cells. Nanoscale 4:110–112
Yu D, Wang D, Zhu FG et al (2009) Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem 52:5108–5114
Yu C, Hu Y, Duan J et al (2011a) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS ONE 6:e24077
Yu MK, Kim D, Lee IH et al (2011b) Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 7:2241–2249
Zhang P, Zhao N, Zeng Z et al (2009) Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab Invest 89:1423–1432
Zhang M, Fabiilli ML, Haworth KJ et al (2010) Initial investigation of acoustic droplet vaporization for occlusion in canine kidney. Ultrasound Med Biol 36:1691–1703
Zhang K, Sefah K, Tang L et al (2012) A novel aptamer developed for breast cancer cell internalization. Chem Med Chem 7:79–84
Zhao N, Bagaria HG, Wong MS et al (2011) A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol 9:2
Zhao Y, Duan S, Zeng X et al (2012) Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 9:1705–1716
Zhou J, Rossi JJ (2011) Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol 721:355–371
Zhou J, Li H, Li S et al (2008) Novel dual inhibitory function aptamer–siRNA delivery system for HIV-1 therapy. Mol Ther 16:1481–1489
Zhou J, Swiderski P, Li H et al (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37:3094–3109
Zhou J, Shu Y, Guo P et al (2011) Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 54:284–294
Zhu G, Meng L, Ye M et al (2012) Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J 7:1630–1636
Zueva E, Rubio LI, Duconge F et al (2011) Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int J Cancer 128:797–804
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ray, P., Viles, K.D., Soule, E.E. et al. Application of Aptamers for Targeted Therapeutics. Arch. Immunol. Ther. Exp. 61, 255–271 (2013). https://doi.org/10.1007/s00005-013-0227-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-013-0227-0